New drug SHR-A1811 targets Hard-to-Treat cancers in early trial
NCT ID NCT04446260
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a drug called SHR-A1811 in 396 people with advanced solid tumors that have HER2 expression or mutations and have stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body, while also looking for signs of tumor shrinkage. The drug is given by IV infusion, and the study is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (an antibody-drug conjugate given by IV infusion)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors that have HER2 mutations or overexpression.
- What could go wrong
- This is an early Phase 1 trial focused on safety and dosing, not yet proven to work. Side effects are possible, and the drug may not shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Hospital
Melbourne, 3004, Australia
-
Asan Medical Center
Seoul, 5505, South Korea
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Chang Gung Memorial Hospital, Linkou
Taoyuan, 333, Taiwan
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Fudan University Shanghai cancer center
Shanghai, Shanghai Municipality, 200032, China
-
Fudan Unversity Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Cancer Hospital
Fujian, Fuzhou, 350000, China
-
Greenville Hospital System
Greenville, South Carolina, 29605, United States
-
Henan cancer Hospital
Zhengzhou, Henan, 450003, China
-
Hubei cancer hospital
Wuhan, Hubei, 430079, China
-
Hunan cancer hospital
Changsha, Hunan, 410031, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210000, China
-
Macquarie University Hospital
Macquarie, New South Wales, 2109, Australia
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Montefiore-Einstein Center for Cancer Care
The Bronx, New York, 10461, United States
-
Nanfang Hospital
Guangzhou, Guangdong, 510120, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
National Cheng Kung University Hospital
Tainan, 70457, Taiwan
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
-
Peninsula and South Eastern Haematology & Oncology Group
Frankston, Victoria, 3199, Australia
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, 3080, South Korea
-
Shanghai Jiao Tong University School of Medicine Renji Hospital
Shanghai, Shanghai Municipality, 200032, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, 030000, China
-
Shengjing Hospital of China medical university
Shengyang, Liaoning, 110022, China
-
Sichuan Cancer Hospital
Chengdu, Sichuan, 610042, China
-
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, 5042, Australia
-
Sun Yat-Sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
-
The first affiliated hospital of bengbu medical college
Bengbu, Anhui, 233000, China
-
The second affiliated hospital Zhejiang university school of medicine
Hangzhou, Zhejiang, 310014, China
-
Tianjin medical university cancer institute&hoospital
Tianjin, Tianjin Municipality, 300181, China
-
Xiangya hospital central south university
Changsha, Hunan, 410008, China
-
Zhejiang provincial people's hospital
Hangzhou, Zhejiang, 310014, China
-
Zhongnan hospital of Wuhan university
Wuhan, Hubei, 430062, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Oral drug elraglusib aims to tame advanced solid tumors
- Experimental drug SHR-7367 takes first step against advanced cancers